T1	Participants 25 66	men with locally advanced prostate cancer
T2	Participants 518 711	945 eligible men with locally advanced prostate cancer were enrolled in a phase 3 trial (RTOG 85-31) and randomized to RT and immediate goserelin or RT alone followed by goserelin at recurrence
T3	Participants 763 786	for 788 (83%) subjects.
